Osteoporosis Canada advises individuals on denosumab therapy to discuss their treatment with their physician prior to delaying therapy, stopping therapy or missing a scheduled dose.   Denosumab (Prolia) has been […]

Osteoporosis Canada is saddened to announce the passing of Dr. Timothy M. Murray, founding member of Osteoporosis Canada. Dr. Murray was the Emeritus Professor of Medicine at the University of […]

On January 18, 2023, INOVAIT and the Government of Canada announced a major investment in the field of image-guided therapy (IGT).

WILLS AND ESTATES Help Canadians Affected by Osteoporosis by Leaving a Gift in Your Will When you leave a gift to Osteoporosis Canada in your Will, you can feel confident […]

On behalf of Osteoporosis Canada’s Scientific Advisory Consultants and Osteoporosis Canada, we would like to announce this year’s Lindy Fraser Award winner as chosen by the members of the SAC. […]

Bisphosphonate therapy – long term use Recently a study published by Drieling et al in JAGS 2017 described the results of a cohort study of 5120 older women with an […]

Denosumab (Prolia) has been shown to reduce the risk of fracture in postmenopausal women and men ≥50 years old with osteoporosis. It has also been approved for steroid induced bone […]

OSTEOPOROSIS AND OSTEOARTHRITIS The prefix “osteo” (which means “bone”) is the only thing that osteoporosis and osteoarthritis have in common. Despite the fact that osteoporosis, arthritis and osteoarthritis (a form […]

NUTRITION Nutrition, especially calcium, plays an important role in preventing osteoporosis. In people who have healthy bones, adequate calcium intake on a daily basis is necessary to maintain bone health. […]